An Error Was Encountered

Error Number: 1054

Unknown column 'cache_on' in 'field list'

UPDATE `aff_pdf_cache` SET `cache` = 'a:10:{i:0;O:8:\"stdClass\":13:{s:2:\"id\";s:6:\"271336\";s:6:\"status\";s:8:\"verified\";s:11:\"author_name\";s:7:\"Webinar\";s:9:\"author_id\";s:1:\"0\";s:14:\"author_website\";s:36:\"\";s:5:\"title\";s:184:\"China: Compliance Processes for Life Science Products: Company Establishment, Clinical Trials, Registrations, Renewals and Supply Chain Considerations -Webinar By GlobalCompliancePanel\";s:11:\"description\";s:1368:\"Overview: This China life science compliance based webinar will discuss the regulatory structure and requirements for compliance with Chinese SFDA regulations for Pharmaceuticals, Medical Devices, Biologics and Combination Products.\n\nWhy should you attend: China has been improving its regulatory regime governing the food and pharmaceutical industry in recent years. In 2010, by promulgating the amended GMP and amending GLP, GCP, GSP and other regulations, China will further align the country with international standards of practice. For manufacturers and distributors of drugs and medical devices in China, it is important to pay close attention to the pace at which SFDA implements these changes and to make changes to their standard operating procedures when necessary to ensure compliance with the evolving regime.\n\nThis course specifically focuses on the overall regulatory compliance requirements and procedures for Pharmaceuticals, Medical Devices, Biologics and Combination Products in China. The course will cover topics relating to pre-clinical and clinical requirements, as well as, addressing the structure of the regulatory agencies in China. Content will also include descriptions of the methods by which regulators in the SFDA process filings and registrations and what is expected in the authorization and dossier maintenance of licensed products. \";s:5:\"thumb\";s:118:\"images/t/2714/china-compliance-processes-for-life-science-products-company-establishment-clinical-trials-registrat.jpg\";s:6:\"thumb2\";s:119:\"images/t2/2714/china-compliance-processes-for-life-science-products-company-establishment-clinical-trials-registrat.jpg\";s:9:\"permalink\";s:100:\"china-compliance-processes-for-life-science-products-company-establishment-clinical-trials-registrat\";s:5:\"pages\";s:1:\"2\";s:6:\"rating\";s:1:\"0\";s:5:\"voter\";s:1:\"0\";}i:1;O:8:\"stdClass\":13:{s:2:\"id\";s:6:\"354891\";s:6:\"status\";s:8:\"verified\";s:11:\"author_name\";s:9:\"lotuslabs\";s:9:\"author_id\";s:5:\"36360\";s:14:\"author_website\";s:0:\"\";s:5:\"title\";s:53:\"Utilities & Features of Bio Clinical Laboratories\";s:11:\"description\";s:365:\"In today’s evolving medical landscape bio clinical laboratories have a crucial role to play in drug development and new treatment discovery. They are full service clinical laboratories having a vast experience in diagnostic medicine and other types of research activities. Bio clinical laboratories are known for their expert physicians and advanced services.\";s:5:\"thumb\";s:65:\"images/t/3549/utilities-features-of-bio-clinical-laboratories.jpg\";s:6:\"thumb2\";s:66:\"images/t2/3549/utilities-features-of-bio-clinical-laboratories.jpg\";s:9:\"permalink\";s:47:\"utilities-features-of-bio-clinical-laboratories\";s:5:\"pages\";s:1:\"2\";s:6:\"rating\";s:1:\"0\";s:5:\"voter\";s:1:\"0\";}i:2;O:8:\"stdClass\":13:{s:2:\"id\";s:6:\"568621\";s:6:\"status\";s:8:\"verified\";s:11:\"author_name\";s:9:\"george002\";s:9:\"author_id\";s:6:\"625044\";s:14:\"author_website\";s:0:\"\";s:5:\"title\";s:110:\"2014 Japanese Clinical Chemistry and Immunodiagnostics Market- Strategic Analysis & Emerging Opportunities\";s:11:\"description\";s:9382:\"Order report “2014 Strategies for the Japanese Clinical Chemistry and Immunodiagnostics Market ” by calling at +1 888 391 5441 OR send an email on with Japanese Clinical Chemistry and Immunodiagnostics Market in subject line and your contact details.\n“2014 Strategies for the Japanese Clinical Chemistry and Immunodiagnostic Market” is a new strategic analysis of major business opportunities emerging in the Japanese clinical chemistry and immunodiagnostic markets during the next five years. The report explores future trends in the Japanese market; provides estimates of the specimen, test and sales volumes, as well as major suppliers’ sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.\n\nThe report provides five-year volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in hospitals, commercial laboratories, physician offices, and ambulatory care centers, including controls, calibrators and consumables.\n\nRationale\nThe clinical chemistry and immunodiagnostic markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, are already resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.\n\nStrategic Recommendations\n- New product development opportunities with significant market appeal.\n- Alternative market penetration strategies.\n- Potential market entry barriers and risks.\n\nCompetitive Assessments\n- Strategic assessments of major suppliers and emerging market entrants, including their sales, product\nportfolios, marketing tactics, collaborative arrangements and new products in R&D. \n\n- The companies analyzed in the report include Abbott, AdnaGen, Agilent, Alere, Beckman Coulter/Danaher, Biomedical Diagnostics, bioMerieux, Bio-Rad, DiaSorin, Eiken, Fujirebio/Innogenetics, IL, Kyowa Medex, Ortho-Clinical Diagnotics, Roche, Siemens, Sysmex, Thermo Fisher, Tosoh, Wako, Wallac/PE.\n\n Complete report is available @ .\nTests Analyzed in the Report:\n\nRoutine Clinical Chemistry\nAlbumin, Alkaline Phosphatase, ALT/SGPT, Ammonia, Amylase, AST/SGOT, Bilirubin, Total,\nBUN (Blood Urea Nitrogen), Calcium, Cardio CRP, Carbon Dioxide/Bicarbonate, Chloride,\nCholesterol, Creatine Kinase (CK), CK-MB, Creatinine, CRP, Ferritin, GGT, Glucose,\nHDL Cholesterol, Homocysteine, Iron, LDH, LDL Cholesterol, Magnesium, Phosphorus,\nPotassium, Protein, Total, Sodium, Triglycerides, Troponin, Uric Acid.\n\nTherapeutic Drug Monitoring (TDM)\nAmikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam,\nLithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Sirolimus,\nTacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid, Vancomycin.\n\nEndocrine Function\nCortisol, Estradiol, FSH, HCG, Gastrin, LH, Progesterone, PTH/IO PTH,\nProlactin, T3, T3 Uptake, Free T3, T4, Free T4, TBG, Testosterone,\nThyroglobulin Ab, TPO Ab, TSH.\n\nTumor Markers and Special Chemistry\nAFP, CA 15-3/27-29, CA 19-9, CEA, Ferritin, Follate (Folic Acid),\nGlycosylated Hemoglobin, HCG, 25-Hydroxy Vitamin D2 and D3, Occult Blood,\nPAP, PSA, Thyroglobulin, Vitamin B-12.\n\nImmunoproteins\nC3, C4, Free Light Chains, Haptoglobin, IgA, IgE Specific, IgE Total, IgG, IgM,\nImmunofixation, Prealbumin, Protein Electrophoresis.\n\nDrugs of Abuse\nAmphetamines, Barbiturates, Benzodiazepines, Cannabinoids/Marijuana, Cocaine,\nLSD, Methadone, Methaqualone, Opiates, Phencyclidine (PCP),\nPropoxyphene, Tricyclic Antidepressants.\n\nMarket Segmentation Analysis\n- Comprehensive review of the market dynamics, trends, structure, size, growth, and key suppliers.\n- Test volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays, by market segment:\n° Hospitals\n° Commercial/Private Laboratories\n\nCurrent and Emerging Products\n- Analysis of current and emerging clinical chemistry and immunodiagnostic tests.\n- Review of current instrumentation technologies, and feature comparison of high-, medium-, and low-volume/POC analyzers.\n\nTechnology Review\n- Assessment of current and emerging technologies, and their potential market applications.\n- Comprehensive lists of companies developing or marketing new technologies and products by test.\n\n Buy a copy of report @ .\n\nTable of Contents \nI. Introduction \n\nII. Worldwide Market and Technology Overview \nA. Major Routine Chemistry Tests \n1. Albumin \n2. Alkaline Phosphatase \n3. ALT/SGPT \n4. Ammonia \n5. Amylase \n6. AST/SGOT \n7. Bilirubin, Total \n8. Blood Gases \n9. Blood Urea Nitrogen (BUN) \n10. Calcium \n11. Cardio CRP \n12. Cholesterol \n13. Cholinesterase \n14. CRP \n15. Creatinine \n16. Electrolytes \na. Carbon Dioxide/Bicarbonate \nb. Chloride \nc. Potassium \nd. Sodium \n17. Ferritin \n18. Fructosamine \n19. Gamma-Glutamyl Transpeptidase (GGT) \n20. Glucose \n21. High Density Lipoprotein (HDL) \n22. Homocysteine \n23. Iron \n24. Lactate Dehydrogenase (LDH) \n25. Magnesium \n26. Phosphorus \n27. Protein \n28. Triglycerides \n29. Uric Acid \n30. Troponin \nB. Therapeutic Drug Monitoring (TDM) \n1. Overview \n2. Carbamazepine \n3. Cyclosporin \n4. Digoxin \n5. Everolimus \n6. Gentamicin \n7. Lamotrigine/Lamictal \n8. Levetiracetam \n9. Lidocaine \n10. Lithium \n11. NAPA/Procainamide \n12. Phenytoin \n13. Quinidine \n14. Sirolimus \n15. Tacrolimus \n16. Theophylline \n17. Topirimate \n18. Valproic Acid \n\nC. Endocrine Function Tests \n1. Cortisol \n2. Estradiol \n3. Follicle-Stimulating Hormone (FSH) \n4. Gastrin \n5. Growth Hormone/IGF-1 \n6. Human Chorionic Gonadotropin (HCG) \n7. LH \n8. Progesterone \n9. PTH/IO PTH \n10. Prolactin \n11. T3 \n12. T3 Free \n13. T3 Uptake \n14. T4 (Thyroxine) \n15. T4 Free \n16. TBG \n17. Testosterone \n18. Thyroglobulin Ab \n19. TPO Ab \n20. TSH \n\nD. Tumor Markers And Special Chemistry Tests \n1. AFP \n2. CA 15-3 \n3. CA 19-9 \n4. CA 27-29 \n5. Carcinoembrionic Antigen (CEA) \n6. Folate/Folic Acid \n7. HCG \n8. 25-Hydroxy Vitamin D2 and D3 \n9. Occult Blood \n10. Prostate-Specific Antigen (PSA) \n11. Thyroglobulin \n12. Vitamin B-12 \n\nE. Immunoprotein Tests \n1. Complement \na. C3 \nb. C4 \n2. Free Light Chains \n3. Immunofixation \n4. Immunoglobulins (IgA, IgE, IgG, IgM) \n5. Haptoglobin \n6. Prealbumin \n7. Protein Electrophoresis \n\nF. Drugs of Abuse 1. Overview \n2. Test Methodologies \n3. Amphetamines \n4. Barbiturates \n5. Benzodiazepines \n6. Cannabinoids/Marijuana \n7. Cocaine \n8. Lysergic Acid Diethylamide (LSD) \n9. Methadone \n10. Methaqualone \n11. Opiates \n12. Phencyclidine \n13. Tricyclic Antidepressants \n\nG. Instrumentation Review: Operating characteristics and features of high-, medium-, and low-volume/POC analyzers \n\nH. Major In Vitro Diagnostic Technologies and Their Potential Applications \n1. Monoclonal and Polyclonal Antibodies \n2. Immunoassays \na. Technological Principle \nb. Chemiluminescence \nc. Enzyme Immunoassays (EIA) \n° Overview \n° ELISA \n° EMIT \n° Electrochemical \nd. Radioimmunoassays (RIA) \ne. Immunoprecipitation \nf. Affinity Chromatography \n3. Tandem Mass Spec \n4. IT and Automation \n5. Dry Chemistry 6. Biosensors \nVI. Japan A. Executive Summary \nB. Business Environment \nC. Market Structure \nD. Market Size, Growth and Major Suppliers’ Instrument and Reagent Sales and Market Shares \nX. Major Product Development Opportunities \nXI. Design Criteria for Decentralized Testing Products \nXII. Alternative Market Penetration Strategies \nA. Internal Development \nB. Collaborative Arrangements \nC. University Contracts \nD. Distribution Strategies for Decentralized Testing Markets \n1. Marketing Approaches \n2. Product Complexity \n3. Customer Preference \n4. Established Suppliers \n5. Emerging Suppliers \n6. Major Types of Distributors \n7. Market Segmentation \nXIII. Potential Market Entry Barriers and Risks \nA. Market Maturity \nB. Cost Containment \nC. Competition \nD. Technological Edge and Limitations \nE. Patent Protection \nF. Regulatory Constraints \nG. Decentralized Testing Market Challenges \nXIV. Competitive Assessments \n- Abbott Laboratories - AdnaGen \n- Agilent Technologies \n- Beckman Coulter/Danaher \n- Biomedical Diagnostics \n- BioMerieux \n- Bio-Rad \n- DiaSorin \n- Eiken \n- Fujirebio/Innogenetics \n- Instrumentation Laboratory \n- Kyowa Medex \n- Matritech/Alere \n- Ortho-Clinical Diagnostics \n- Quest Diagnostics \n- Roche \n- Siemens \n- Sysmex \n- Thermo Fisher \n- Tosoh \n- Wako \n- Wallac/PE\n\nContact / Call +1 888 391 5441 for further information on “2014 Strategies for the Japanese Clinical Chemistry and Immunodiagnostics Market” report OR for any other market research and intelligence needs you may have for your business.\n\n\";s:5:\"thumb\";s:118:\"images/t/5687/2014-japanese-clinical-chemistry-and-immunodiagnostics-market-strategic-analysis-emerging-opportunit.jpg\";s:6:\"thumb2\";s:119:\"images/t2/5687/2014-japanese-clinical-chemistry-and-immunodiagnostics-market-strategic-analysis-emerging-opportunit.jpg\";s:9:\"permalink\";s:100:\"2014-japanese-clinical-chemistry-and-immunodiagnostics-market-strategic-analysis-emerging-opportunit\";s:5:\"pages\";s:2:\"17\";s:6:\"rating\";s:1:\"0\";s:5:\"voter\";s:1:\"0\";}i:3;O:8:\"stdClass\":13:{s:2:\"id\";s:4:\"1313\";s:6:\"status\";s:8:\"verified\";s:11:\"author_name\";s:4:\"rika\";s:9:\"author_id\";s:2:\"60\";s:14:\"author_website\";s:0:\"\";s:5:\"title\";s:19:\"Clinical Psychology\";s:11:\"description\";s:304:\"At the moment most clinical psychologists work in one or more of the following services: adult mental health, child and adolescent, older adults, learning difficulties, primary care, long term mental health, health psychology (general medicine), substance misuse, neuropsychology and forensic psychology.\";s:5:\"thumb\";s:35:\"images/t/14/clinical-psychology.jpg\";s:6:\"thumb2\";s:36:\"images/t2/14/clinical-psychology.jpg\";s:9:\"permalink\";s:19:\"clinical-psychology\";s:5:\"pages\";s:1:\"4\";s:6:\"rating\";s:1:\"1\";s:5:\"voter\";s:1:\"1\";}i:4;O:8:\"stdClass\":13:{s:2:\"id\";s:4:\"1315\";s:6:\"status\";s:8:\"verified\";s:11:\"author_name\";s:4:\"rika\";s:9:\"author_id\";s:2:\"60\";s:14:\"author_website\";s:0:\"\";s:5:\"title\";s:62:\"Scientific and Professional Foundations of Clinical Psychology\";s:11:\"description\";s:586:\"The founder of clinical psychology, Lightner Witmer, established the ?rst psychology clinic and training program in 1896. Later, Witmer founded and edited the ?rst scienti?c and professional journal for the developing ?eld, Psychological Clinic. Thus, even at the outset, there was an implicit recognition of the value of integrated science and practice. Nevertheless, the research methodologies which characterized most early clinical psychology investigations (and many of the conclusions derived therefrom) are generally regarded as ?awed, even primitive, by today’s standards.\";s:5:\"thumb\";s:77:\"images/t/14/scienti-c-and-professional-foundations-of-clinical-psychology.jpg\";s:6:\"thumb2\";s:78:\"images/t2/14/scienti-c-and-professional-foundations-of-clinical-psychology.jpg\";s:9:\"permalink\";s:61:\"scienti-c-and-professional-foundations-of-clinical-psychology\";s:5:\"pages\";s:2:\"12\";s:6:\"rating\";s:1:\"0\";s:5:\"voter\";s:1:\"0\";}i:5;O:8:\"stdClass\":13:{s:2:\"id\";s:4:\"1323\";s:6:\"status\";s:8:\"verified\";s:11:\"author_name\";s:4:\"rika\";s:9:\"author_id\";s:2:\"60\";s:14:\"author_website\";s:0:\"\";s:5:\"title\";s:29:\"Basics of Clinical Psychology\";s:11:\"description\";s:444:\"The incidence of psychological disorders is relatively high. This handout introduces clinical
\npsychology — the application of scientific psychology to the understanding and resolution of
\nhuman psychological problems. We’ll look at ways in which mental disorders can be classified
\nand the issues that are raised by classifying people. Finally we’ll overview the major historical approaches to psychopathology.\";s:5:\"thumb\";s:45:\"images/t/14/basics-of-clinical-psychology.jpg\";s:6:\"thumb2\";s:46:\"images/t2/14/basics-of-clinical-psychology.jpg\";s:9:\"permalink\";s:29:\"basics-of-clinical-psychology\";s:5:\"pages\";s:1:\"8\";s:6:\"rating\";s:1:\"0\";s:5:\"voter\";s:1:\"0\";}i:6;O:8:\"stdClass\":13:{s:2:\"id\";s:4:\"1329\";s:6:\"status\";s:8:\"verified\";s:11:\"author_name\";s:4:\"rika\";s:9:\"author_id\";s:2:\"60\";s:14:\"author_website\";s:0:\"\";s:5:\"title\";s:25:\"The Clinical Psychologist\";s:11:\"description\";s:478:\"The field of developmental psychopathology has expanded rapidly. Principles from classical developmental theory are applied to the investigation of psychopathology and other
\nclinical phenomena. Through this integration of developmental and clinical psychology, knowledge about normal development informs issues in psychopathology, and discoveries in the fields of psychopathology and atypical development en-
\nhance understanding of normative developmental processes.\";s:5:\"thumb\";s:41:\"images/t/14/the-clinical-psychologist.jpg\";s:6:\"thumb2\";s:42:\"images/t2/14/the-clinical-psychologist.jpg\";s:9:\"permalink\";s:25:\"the-clinical-psychologist\";s:5:\"pages\";s:2:\"28\";s:6:\"rating\";s:1:\"2\";s:5:\"voter\";s:1:\"3\";}i:7;O:8:\"stdClass\":13:{s:2:\"id\";s:4:\"2599\";s:6:\"status\";s:8:\"verified\";s:11:\"author_name\";s:6:\"shinta\";s:9:\"author_id\";s:3:\"377\";s:14:\"author_website\";s:0:\"\";s:5:\"title\";s:99:\"Clinical malnutrition in severe traumatic brain injury : Factors associated and outcome at 6 months\";s:11:\"description\";s:1807:\"Traumatic brain injury increases the metabolic response of body, and therefore nutritional
\ndemands. This study was undertaken to evaluate various clinical features of malnutrition in TBI and
\ntheir influence on neurological outcome. Eighty eight adult patients within 24 hours of TBI admitted
\nwith GCS 4 to 8 without serious systemic disorder were enrolled for the study. They were monitored
\nserially for various clinical features of malnutrition till 3 weeks and outcome assessed at 6 months.
\nEvery week there was a significant increase in number of patients with various clinical features of
\nmalnutrition. Pedal edema was the most frequent sign present in 70% of patients at three weeks,
\nfollowed by skeletal prominence (19%) and cheilosis (12%). Clinical malnutrition showed significant
\nassociation with poorer GCS (p=0.03), admission hypoproteinemia (p=0.03), and delayed full enteral
\nfeeding (p<0.001). Unfavorable outcome at 6 months was noted in 30 out of 37 patients who had
\nclinical malnutrition as compared to 3 out of 15 patients who had no clinical features of malnutrition
\n(odds ratio 17.2, p<0.001). In multivariate analysis, clinical malnutrition was significantly associated
\nwith unfavorable outcome independent of GCS (p=0.002). Analysis of individual clinical markers
\nrevealed pedal edema as the only single clinical marker with significant influence on unfavorable
\noutcome at 6 months (p=0.01). Clinical malnutrition developed more among patients with poorer
\nGCS, admission hypoproteinemia, delayed full enteral feeding, and was associated with unfavorable
\noutcome at 6 months. Among the various clinical markers, only pedal edema showed independent
\nassociation with unfavorable outcome.\";s:5:\"thumb\";s:113:\"images/t/26/clinical-malnutrition-in-severe-traumatic-brain-injury-factors-associated-and-outcome-at-6-months.jpg\";s:6:\"thumb2\";s:114:\"images/t2/26/clinical-malnutrition-in-severe-traumatic-brain-injury-factors-associated-and-outcome-at-6-months.jpg\";s:9:\"permalink\";s:97:\"clinical-malnutrition-in-severe-traumatic-brain-injury-factors-associated-and-outcome-at-6-months\";s:5:\"pages\";s:1:\"5\";s:6:\"rating\";s:3:\"2.6\";s:5:\"voter\";s:1:\"5\";}i:8;O:8:\"stdClass\":13:{s:2:\"id\";s:4:\"4423\";s:6:\"status\";s:8:\"verified\";s:11:\"author_name\";s:6:\"shinta\";s:9:\"author_id\";s:3:\"377\";s:14:\"author_website\";s:0:\"\";s:5:\"title\";s:118:\"The effects of coffee consumption on lipid peroxidation and plasma total homocysteine concentrations: a clinical trial\";s:11:\"description\";s:1402:\"Despite extensive research, the cardiovascular effects of coffee consumption in humans remain controversial. Our aim was to investigate
\nthe excretion of coffee phenols and the effects of filtered coffee consumption on oxidative stress and plasma homocysteine (tHcy)
\nconcentration in humans. The study consisted of a multiple-dose clinical supplementation trial and a single-dose study. In the long-term trial,
\n43 healthy nonsmoking men optionally consumed daily either no coffee, 3 cups (450 mL), or 6 cups (900 mL) of filtered coffee for 3 weeks,
\nwhile in the short-term study 35 subjects consumed a single dose of 0, 1 (150 mL), or 2 cups (300 mL) of coffee. Long-term consumption of
\ncoffee increased the urinary excretion of caffeic and ferulic acid. The change in the total excretion of phenolic acids in 3 and 6 cups groups
\nrepresented 3.8 and 2.5% of the amount ingested daily. Plasma tHcy concentrations increased nonsignificantly, but the consumption of coffee
\nhad neither short-nor long-term effects on lipid peroxidation or the activity of measured antioxidant enzymes. In conclusion, the consumption
\nof filtered coffee does not have any detectable effects on lipid peroxidation in healthy nonsmoking men. The effect of coffee consumption on
\ntHcy concentrations needs further investigation.
\nD 2004 Elsevier Inc. All rights reserved.\";s:5:\"thumb\";s:133:\"images/t/45/the-effects-of-coffee-consumption-on-lipid-peroxidation-and-plasma-total-homocysteine-concentrations-a-clinical-trial.jpg\";s:6:\"thumb2\";s:134:\"images/t2/45/the-effects-of-coffee-consumption-on-lipid-peroxidation-and-plasma-total-homocysteine-concentrations-a-clinical-trial.jpg\";s:9:\"permalink\";s:117:\"the-effects-of-coffee-consumption-on-lipid-peroxidation-and-plasma-total-homocysteine-concentrations-a-clinical-trial\";s:5:\"pages\";s:1:\"8\";s:6:\"rating\";s:1:\"0\";s:5:\"voter\";s:1:\"0\";}i:9;O:8:\"stdClass\":13:{s:2:\"id\";s:4:\"4877\";s:6:\"status\";s:8:\"verified\";s:11:\"author_name\";s:6:\"shinta\";s:9:\"author_id\";s:3:\"377\";s:14:\"author_website\";s:0:\"\";s:5:\"title\";s:83:\"ETHICAL ISSUES IN THE DESIGN AND CONDUCT OF CLINICAL TRIALS IN DEVELOPING COUNTRIES\";s:11:\"description\";s:1156:\"THERE has been considerable controversy about
\nthe ethics of clinical trials that are sponsored or
\nconducted by groups in industrialized countries but
\ncarried out in developing countries.1-8 The National
\nBioethics Advisory Commission, of which we serve as
\nchairman and executive director, respectively, has recently
\naddressed these and related issues.9 International
\ncollaborative research covers a broad spectrum of
\nmethods, topics, and research strategies. In this essay,
\nwe discuss ethical issues in the design and conduct of
\nclinical trials in developing countries. In particular, we
\nfocus on phase 3 and other drug trials that, if successful,
\ncan lead to the use of effective new treatments.
\nClinical trials should not exploit the subjects who
\nagree to participate in them.10 The United States is
\none of several countries that have developed substantive
\nethical standards (based on the principles of justice
\nand individual autonomy) for conducting clinical research,
\nas well as a required set of procedures for implementing
\nthe standards.\";s:5:\"thumb\";s:99:\"images/t/49/ethical-issues-in-the-design-and-conduct-of-clinical-trials-in-developing-countries.jpg\";s:6:\"thumb2\";s:100:\"images/t2/49/ethical-issues-in-the-design-and-conduct-of-clinical-trials-in-developing-countries.jpg\";s:9:\"permalink\";s:83:\"ethical-issues-in-the-design-and-conduct-of-clinical-trials-in-developing-countries\";s:5:\"pages\";s:1:\"4\";s:6:\"rating\";s:7:\"3.33333\";s:5:\"voter\";s:1:\"3\";}}', `cache_on` = '2015-02-28 08:55:28' WHERE `aff_id` = '1748854'